after joining the study you attend a first visit at the clinic where basic health information is recorded and a physical examination is performed.

the purpose of this visit is to collect data that will be used as a reference point for later comparisons.

based on a computer‑generated list you are assigned to receive either ly4005130 or a placebo.

the assignment is done in a double blind manner, meaning that neither you nor the study staff know which product you receive.

during the same visit you receive the assigned product by intravenous infusion, which means the solution is delivered directly into a vein.

the study medication is supplied as a solution for injection; the recorded dose is 0 mg (milligram) as specified in the protocol.

throughout the 24‑week study period you return to the clinic at regular intervals that are defined by the study schedule.

at each visit safety checks are performed, vital signs are measured, and skin areas are photographed to evaluate changes in vitiligo.

these visits also allow the study team to monitor any side effects and to record any additional doses of the study product if required by the protocol.

according to the study schedule you may receive additional intravenous infusions of the assigned product during the 24‑week period.

each infusion follows the same procedure as the first one, using the same dose and administration method.

at week 24 you attend a final clinic visit where a comprehensive evaluation is performed.

the primary outcome measured is the percentage of participants achieving a facial vitiligo area scoring index (f‑vasi) of 75, which reflects improvement of skin pigmentation.

after this visit the study participation ends and no further study medication is administered.